Corrigendum to “Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of EGFR-mutated advanced NSCLC patients”

ESMO Real World Data and Digital Oncology 2026 Open access

Read full text
Authors: Federica Corso, Paolo Baili, F. Scotti, L. Mazzeo, Vittorio Torri, G. Lo Russo, C. Proto, C. Giani, M. Ganzinelli, Rosa Maria Di Mauro, A. Cappozzo, A.M. Paganoni
+2 more A. Prelaj, F. Ieva
DOI: 10.1016/j.esmorw.2026.100686
Cited by: 0

Abstract

The authors regret the need to change the funding statement to ‘This work was supported by 5 per mille funds for scientific research—Italian Ministry of University and Research (MUR; no grant number)’.

Fields of Study & Subjects

Health Systems Economic Evaluations Quality of Life Lung Cancer Treatments and Mutations Economic and Financial Impacts of Cancer

Publication details

Journal / source
ESMO Real World Data and Digital Oncology
Volume
11
Pages
100686–100686
Publication date
9 February 2026
Language
EN